Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 3 of 7
A Study of Paliperidone Palmitate 6-Month Formulation
Janssen Research & Development
NCT03345342
Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States
University of Maryland, Baltimore
NCT01425671
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
FORUM Pharmaceuticals
NCT01716975
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
Forest Laboratories
NCT01412060
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
FORUM Pharmaceuticals
NCT01714661
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
Forest Laboratories
NCT00694707
Pediatric Open-Label Extension Study
Sumitomo Pharma America
NCT01914393
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
Teva Branded Pharmaceutical Products R&D
NCT05693935
Inpatient Evaluation of Adults With Schizophrenia
National Institute of Mental Health (NIMH)
NCT00001247
Relapse Prevention Study in Patients With Schizophrenia
Vanda Pharmaceuticals
NCT01291511
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
Hoffmann-La Roche
NCT01192867
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Hoffmann-La Roche
NCT01192906
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
Boehringer Ingelheim
NCT04846881
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
Targacept
NCT01488929
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Eli Lilly and Company
NCT00103571
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
Eli Lilly and Company
NCT00100776
Prospective Studies of the Pathogenesis of Schizophrenia
University of North Carolina, Chapel Hill
NCT00877552
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
Vanda Pharmaceuticals
NCT00254202
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
Karuna Therapeutics
NCT04820309
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Alkermes
NCT02694328
The Management of Schizophrenia in Clinical Practice (MOSAIC)
Genentech
NCT01746134
PET Scanning in Parkinson s Disease
National Institute of Mental Health (NIMH)
NCT00024622
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Sumitomo Pharma America
NCT00790192
Improving Care and Reducing Cost Study
Northwell Health
NCT02364544
Cognitive Skills Training Using Computer for Patients With Severe Mental Illness
Nathan Kline Institute for Psychiatric Research
NCT01036282
A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines
US Department of Veterans Affairs
NCT00013000
Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia
University of Miami
NCT00356317
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
ACADIA Pharmaceuticals
NCT02970292
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
AbbVie
NCT05227690
Comparison of Video Consent Versus Routine Consent for Participation in Research Studies
University of California, San Diego
NCT00430391
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia
Janssen Research & Development
NCT01559272
Pediatric Schizophrenia Efficacy and Safety Study
Sumitomo Pharma America
NCT01911429
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Hoffmann-La Roche
NCT00616798
Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia
FORUM Pharmaceuticals
NCT00968851
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
AbbVie
NCT04578756
Improving Health Services for Veterans With Schizophrenia
US Department of Veterans Affairs
NCT00012961
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
Janssen Scientific Affairs
NCT02600741
Early Detection and Intervention for the Prevention of Psychosis
MaineHealth
NCT00531518
An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
Alkermes
NCT01895452
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
Cephalon
NCT00772005
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
National Institute of Mental Health (NIMH)
NCT00942981
Relative Bioavailability of LY03010 Compared to Listed Drug
Luye Pharma Group
NCT04922593
A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes
NCT02669758
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia
Alkermes
NCT02873208
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00634348
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
AstraZeneca
NCT00090324
Multicenter, Open-label, Safety and Tolerability Study
Otsuka Pharmaceutical Development & Commercialization
NCT01649557
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Sumitomo Pharma America
NCT01143077
The Appeal and Impact of E-cigarettes in Smokers With SMI
Dartmouth-Hitchcock Medical Center
NCT03050853
The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.
US Department of Veterans Affairs
NCT00466323
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.